Erenumab - CISMeF

Preferred Label : Erenumab;

NCIt definition : A human immunoglobulin G2 (IgG2) monoclonal antibody targeting calcitonin gene-related peptide receptor (CGRPR), that can be used in the preventive treatment of migraine. Upon subcutaneous administration, erenumab specifically targets, binds to and blocks the activity of CGRPR. This may relief CGRPR-triggered migraine.;

UNII : I5I8VB78VT;

CAS number : 1582205-90-0;

Drug name : Aimovig;

Molecule name : AMG 334; AMG-334;

NCI Metathesaurus CUI : CL1382459;

Details

Origin ID

C169958;

UMLS CUI

C4542165;

Currated CISMeF NLP mapping
- Erenumab [Anticorps monoclonal]
- Erenumab [ICD-11 Extension code]
- Erenumab [SMS substance]
- Erenumab (substance) [SNOMED CT concept]
- erenumab [MeSH Supplementary Concept]
- erenumab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Erenumab (substance) [SNOMED CT concept]
- Product containing erenumab (medicinal product) [SNOMED CT concept]
- erenumab [MeSH Supplementary Concept]
- erenumab [ATC Code]
Validated automatic mappings to BTNT
- erenumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients